AOR.L Regulatory News (AOR)

AorTech International plc

(the "Company")

Result of AGM and Share Capital Reorganisation

AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, is pleased to announce that at the Annual General Meeting held today, all the resolutions were duly passed.

Accordingly, the proposed share consolidation of the Company's share capital ("Share Capital Reorganisation") will become effective on the record date, being 6.00 p.m. today, 24 September 2015.

Under the Share Capital Reorganisation each of the ordinary shares of 250 pence each in the capital of the Company ("the Existing Ordinary Shares") which at 6pm on 24 September 2015 are shown in the books of the Company to be in issue shall be sub-divided into one new ordinary share of 5 pence in the capital of the Company (each a "New Ordinary Share") and one new deferred share of 245 pence in the capital of the Company (each a "Deferred Share"), such shares having the rights and being subject to the restrictions set out in the Company's articles of association.

Application has been made for the 4,832,778 New Ordinary Shares to be admitted to trading on AIM ("Admission") and dealings are expected to commence at 8.00 a.m. on 25 September 2015 with the existing ISIN GB0033360586.

Following the Share Capital Reorganisation there will be 4,832,778 New Ordinary Shares in issue. The Company does not hold any shares in treasury. Therefore the total number of shares with voting rights in the Company following Admission will be 4,832,778. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

This information is provided by RNS

For further information contact:

AorTech International plc 

Eddie McDaid, Chief Executive Tel: +44 (0)7802 920869

AorTech International plc 

Bill Brown, Chairman Tel: +44 (0)7730 718296 

finnCap Limited

Jonny Franklin-Adams/ Giles Rolls Tel: +44 20 7220 0500